We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
As would-be rivals struggled with winning FDA approvals in the last few years, GlaxoSmithKline's key respiratory franchise has reaped the benefit. But now, the company is suffering a setback of its own.
US regulatory advisors are questioning the effectiveness of GlaxoSmithKline’s biologic Nucala as a treatment for patients experiencing a sudden worsening of chronic obstructive pulmonary disorder (COPD).